Yong Chang, Ph.D., is senior vice president of development at Korro Bio, where he oversees all aspects of development. Applying over 20 years of bio-pharmaceutical R&D and operating experience, Yong is accountable for ensuring optimal development of company’s therapeutic candidates, from late-stage discovery to early clinical PoC.
Prior to joining Korro Bio in 2019, he held the position of vice president of preclinical and translational sciences at Intellia Therapeutics, a leading gene editing company. In this role, Yong was responsible for leading all aspects of preclinical and translational R&D, and was instrumental in identifying the first development candidate of a systemically delivered gene editing product. Before joining Intellia in 2015, he held the position of vice president of biology and translational research at Aileron Therapeutics, where he was responsible for leading the R&D strategy, including the implementation of cell and molecular biology and medicinal chemistry road maps. Prior to joining Aileron in 2011, Yong was the head of translational pharmacology at MedImmune, Inc. (AstraZeneca subsidiary).
Yong received his Ph.D. from Penn State University and completed his postdoctoral training at Massachusetts General Hospital/Harvard Medical School.